ClinicalTrials.gg
CompletedNCT05846503iHEART-SAUpdated Dec 10, 2025

iHEART-SA Intervention Study

An interventional study of 1. Quality and info management system in Hypertension and HIV, sponsored by University of Witwatersrand, South Africa. Completed at 1 site in South Africa. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-10.

Sponsored by University of Witwatersrand, South Africa · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
4,378
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Using qualitative data during the formative phase the IHEART-SA research study filled deficiencies in knowledge regarding: 1) what barriers exist to integrating hypertension care within the HIV care setting in South Africa and, 2) how a hypertension care intervention can be adapted to effectively and sustainably function in this care setting. These data have been used to design a context-relevant intervention package for implementation in the next phase of effectiveness-implementation testing, answering the research question: How does an intervention aimed at enhancing hypertension diagnosis and management in people living with HIV improve the delivery of guideline-recommended care in primary healthcare clinics in Gauteng, South Africa, and hypertension control among patients?

The study will use an effectiveness-implementation study design. This design allows for the testing of strategies to promote integration of proven interventions in real-world practice (i.e., implementation strategies), while simultaneously assessing clinical effectiveness (i.e., patient level outcomes). For this the study will use a randomized cluster stepped-wedge study design where nine clinics (grouped in clusters of three) will be assigned to a time at which they initiate the intervention.

Read the detailed description

Investigational interventions:

Implementation facilitation of improved hypertension screening and management in the HIV care setting through the iHEART-SA intervention model comprising:

  1. Information management system
  2. Task shifting
  3. Audit and feedback
  4. Healthcare worker education and training
  5. Patient education and support

Study design:

Cluster randomized stepped wedge effectiveness-implementation type 2 hybrid

Study objectives:

  1. Assess the short- and long-term effects of an implementation strategy (i.e., healthcare worker intervention) on the adoption and implementation of hypertension screening and treatment among healthcare workers
  2. Assess the short- and long-term effects of a clinical intervention (i.e., patient-level intervention) on patient blood pressure control among patients living with HIV and hypertension

Duration of participation: 27 months Study duration: 37 months

Intervention audience:

  1. Healthcare workers (nurses and doctors)
  2. Adult patients living with HIV from the 9 primary healthcare clinics
02

Conditions studied

  • Hypertension
  • HIV

Browse trials for

03

In context

Hypertension

6,114 studies on the registry are indexed under Hypertension; 912 are open to participants now.

This study's enrollment of 4,378 is above the median of 100 across 4,575 interventional studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

University of Witwatersrand, South Africa is the lead sponsor of 47 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthcare workers:

  1. Adult >18 years men and women working in clinical roles at the selected clinics
  2. Provide (only those participating in the qualitative components)

Patients:

  1. Adults >18 years living with and hypertension
  2. Enrolled in the study clinic
  3. Willing and able to provide informed consent

Exclusion criteria

Exclusion Criteria:

Patients:

  1. Unable or unwilling to provide
  2. Planning to relocate or change service providers/clinics
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
4,378 participants (actual)

Study arms

  • Other
    Intervention

    Cluster of clinics receiving the five investigational interventions

    Behavioral: 1. Quality and info management system

  • No intervention
    Control

    Standard of care

Interventions

  • Behavioral1. Quality and info management system

    1. The intervention package prioritizes information and quality management with a focus on HTN screening, diagnosis, and treatment. From the point-of-care, flow charts placed in the patient file will ensure that vitals are performed in accordance with national guidelines. 2. The care coordinator will present data to clinic staff in multi-disciplinary meetings, providing an opportunity for programmatic feedback and discussion. 3. Patients will be encouraged to complete the vital signs measurements at each clinic visit. They will be provided with their BP readings and given info about what their reading means. They will be issued with pocket sized color coded booklets providing info on the measurement and what to do to control their BP. 4. Task shifting: A care coordinator will be the champion of the intervention package for the clinic. 5. All staff will receive apt training on how to use the patient flow chart, info management system and how to respond to abnormal BP values.

    Also known as: 2. Case review meetings, 3. Patient health education and support, 4. Task shifting, 5. HCW education and training

06

What researchers measure

Primary outcomes

  1. Healthcare worker

    Difference in percentage of patient visits with recorded BP measurement between intervention and control clinics

    Time frame: 24 months

  2. Patient

    Difference in mean systolic BP between the intervention and control conditions

    Time frame: 12 months

Secondary outcomes

  1. Healthcare worker implementation

    % of healthcare workers who implement the iHEART-SA package as intended at month 12 and month 24

    Time frame: 24 months

  2. Healthcare worker adoption

    Participation rate and representativeness of healthcare workers who adopt the BP screening and treatment model

    Time frame: 24 months

  3. Healthcare worker maintenance - BP measurement

    % of patients who had a BP measurement done at every clinic visit

    Time frame: 12 months

  4. Healthcare worker satisfaction

    % of healthcare workers who are satisfied with all components of the intervention

    Time frame: 24 months

  5. Healthcare worker costing

    Costs of each intervention components will be recorded as healthcare worker time, material costs, and healthcare/monitoring equipment

    Time frame: 27 months

  6. Patient adoption

    Participation rate and representativeness of eligible patients who consent to chart review

    Time frame: 24 months

  7. Patient satisfaction

    % of patients who are satisfied with all components of the intervention

    Time frame: 24 months

  8. Healthcare worker maintenance - BP management

    % of patients who had an elevate BP managed at every visit post intervention

    Time frame: 12 months

07

Study locations

1 site
  • Sunnyside Office Park
    Johannesburg, Gauteng 2193, South Africa
08

References and documents

Publications

  • Gala P, Mugala A, Hickey MD, Ordonez CE, Gimbel S, Galaviz KI, Lalla-Edward ST, Kiggundu JB, Henry DA, Mogaetsho GE, Aifah A, Katahoire A, Semitala F, Hirschhorn LR. Models for Integrated HIV-Hypertension Care: Comparative Analysis of Six Integration Approaches from Implementation Research Projects Across Africa. Res Sq [Preprint]. 2026 Jun 17:rs.3.rs-9464167. doi: 10.21203/rs.3.rs-9464167/v1. PubMed 42370263 ↗
  • Galaviz KI, Patel SA, Siedner MJ, Goss CW, Gumede SB, Johnson LC, Ordonez CE, Laxy M, Klipstein-Grobusch K, Heine M, Masterson M, Mody A, Venter WDF, Marconi VC, Ali MK, Lalla-Edward ST. Integrating hypertension detection and management in HIV care in South Africa: protocol for a stepped-wedged cluster randomized effectiveness-implementation hybrid trial. Implement Sci Commun. 2024 Oct 14;5(1):115. doi: 10.1186/s43058-024-00640-6. PubMed 39402688 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05846503
Lead sponsor
University of Witwatersrand, South Africa
Responsible party
Professor Francois Venter (Executive Director, University of Witwatersrand, South Africa) — Principal investigator
First posted
May 6, 2023
Start date
Jun 1, 2023
Primary completion
May 31, 2025
Completion
Aug 31, 2025
Last update
Dec 10, 2025

Study contacts

Willem DF Venter, MD, PHD
principal investigator · Ezintsha, University of the Witwatersrand

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion